Valsartan - Cilnidipine Combination Tablets
"ATEDIO® Tab." Launches

Mochida Pharmaceutical Co., Ltd. (hereinafter “Mochida Pharmaceutical”) (President, Naoyuki Mochida; headquarters, Tokyo, Japan) started the distribution of valsartan-cilnidipine combination tablets “ATEDIO® Tab.” for treatment of hypertension on May 23, 2014. “ATEDIO® Tab.” was developed by Mochida Pharmaceutical and Ajinomoto Pharmaceuticals Co., Ltd. (hereinafter “Ajinomoto Pharmaceuticals”) (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) jointly, and Ajinomoto Pharmaceuticals obtained the marketing approval on March 24, 2014. “ATEDIO® Tab.” was included in the National Health Insurance drug price list today. “ATEDIO® Tab.” is manufactured by Ajinomoto Pharmaceuticals and distributed by Mochida Pharmaceutical.

“ATEDIO® Tab.” is the first combination tablets of cilnidipine, a long-acting calcium channel blocker that blocks N-type calcium channel, and valsartan, an angiotensin II receptor antagonist, launched in Japan market. The combination between the agents of different action mechanisms is expected to exert good anti-hypertensive effects.

Cilnidipine (Product name: ATELEC® Tab.) blocks both L-type and N-type calcium channels and inhibits blood pressure elevation due to sympathetic nerve hyperactivity as well as suppresses heart rate increase that occurs when blood pressure falls. Valsartan has stable antihypertensive effects and is widely used in treatment of hypertension.

It is often the case with treatment of hypertension that target blood pressures cannot be achieved enough by use of a single antihypertensive agent, and, thus, combination use of different agents that have different action mechanisms is common. In addition, there are a number of patients with hypertension who take other medicines concomitantly with antihypertensive agents. Mochida Pharmaceutical and Ajinomoto Pharmaceuticals expect that “ATEDIO® Tab.” can increase the convenience in medication and this will contribute to treatment and increase of patient’s Quality of Life.

This information of the above will have only minor impact on the business performance of Mochida for the near term.

End
**Brand name**: ATEDIO® Tab.

**Nonproprietary name**: valsartan / cilnidipine

**Dosage form, dose**: oval film-coated tablets

* A tablet contains 80 mg of valsartan and 10 mg of cilnidipine

**Indication**: hypertension

**Dosing regimen**: One tablet once daily orally (80 mg of valsartan and 10 mg of cilnidipine) after breakfast for adult. Should not be used for the first-line treatment of hypertension.

**Package**: 100 tablets (blister cards), 140 tablets (blister cards), 500 tablets (blister cards), 500 tablets (bulk)

**National Health Insurance (NHI) drug price**: ¥134.2 / tablet

**Marketing approval date**: March 24, 2014

**NHI drug price list inclusion date**: May 23, 2014

**Launch date**: May 23, 2014

**Manufacturer**: Ajinomoto Pharmaceuticals Co., Ltd.

**Distributor**: Mochida Pharmaceutical Co., Ltd.

---

**Contact**

Corporate Planning Dept., Ajinomoto Pharmaceuticals Co., Ltd.

TEL: +81-(0)3-6280-9802

E-mail: contact_ajs@ajinomoto.com